Huntington's Disease Market Spotlight 2018-2028 - ResearchAndMarkets.com

DUBLIN--()--The "Market Spotlight: Huntington's Disease" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Huntington's disease market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The author estimates that in 2016 there were 155,620 prevalent cases of Huntington's disease in adults aged 30 years and older worldwide, and forecasts that number to increase to 181,760 prevalent cases by 2025.
  • Northern America is estimated to have the largest prevalence proportion (0.0073%) while Asia has the smallest prevalence proportion (0.0004%).
  • A majority of industry-sponsored drugs in active clinical development for Huntington's disease are in Phase II. Therapies in mid and late-stage development for Huntington's disease focus on a wide variety of targets. Among these therapies, Procysbi, an enteric-coated micro-bead formulation of cysteamine bitartrate, is closest to market. The majority of the pipeline drugs in mid-to-late-stage development for Huntington's disease are administered via the oral route.
  • Valeant Pharmaceuticals' Xenazine and Teva Pharmaceutical's Austedo, which target vesicular monamine transporters, are the only marketed drugs for Huntington's disease. The drugs are administered via the oral route. Austedo, a deuteriumsubstituted analogue of tetrabenazine, was approved by the US Food and Drug Administration (FDA) in April 2017.
  • The topline Phase II trial results for IONIS-HTTRx, VX15, and Nerventra are the high-impact upcoming events in the Huntington's disease space.
  • There were eight licensing and asset acquisition activities involving Huntington's disease drugs during 2013-18, three of which occurred in 2015. The exclusive licensing agreement in 2015 between Neurocrine Biosciences and Mitsubishi Tanabe Pharma to develop and commercialize Neurocrine Biosciences' VMAT2 inhibitor - NBI-98854 - in Japan and certain selected Asian markets, for $115m, was the largest deal during the period.
  • The clinical trials distribution across Phase I-IV indicates that the majority of trials for Huntington's disease have been in early and mid phases of development, with 72.4% of trials in Phase I-II, and only 27.6% in Phase III-IV.
  • The US has a substantial lead in the number of Huntington's disease clinical trials globally. Germany and the UK lead the major EU markets.
  • Clinical trial activity in the Huntington's disease space is dominated by completed trials. Pfizer has the highest number of completed trials for Huntington's disease, with 12 completed trials.
  • Pfizer leads industry sponsors with the highest number of clinical trials for Huntington's disease, followed by Teva and NeuroSearch.

Key Topics Covered:

  1. Key Takeaways
  2. Disease Background
  3. Treatment
  4. Epidemiology
  5. Marketed Drugs
  6. Pipeline Drugs
  7. Key Upcoming Events
  8. Key Regulatory Events
  9. Licensing And Asset Acquisition Deals
  10. Parent Patents
  11. Revenue Opportunity
  12. Clinical Trial Landscape
  13. Bibliography

For more information about this report visit https://www.researchandmarkets.com/research/5msj2k/huntingtons?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs